Treatment options in Alzheimer's disease: maximizing benefit, managing expectations

Dementia and Geriatric Cognitive Disorders
Martin FarlowVojislav Pejovic


Alzheimer's disease (AD) is becoming an increasingly heavy burden on the society of developed countries, and physicians now face the challenge of providing efficient treatment regimens to an ever-higher number of individuals affected by the disease. Currently approved anti-AD therapies - the cholinesterase inhibitors and the N-methyl-D-aspartate receptor antagonist memantine - offer modest symptomatic relief, which can be enhanced using combination therapy with both classes of drugs. Additionally, alternative therapies such as nonsteroidal anti-inflammatory drugs, vitamin E, selegiline, Ginkgo biloba extracts, estrogens, and statins, as well as behavioral and lifestyle changes, have been explored as therapeutic options. Until a therapy is developed that can prevent or reverse the disease, the optimal goal for effective AD management is to develop a treatment regimen that will yield maximum benefits for individual patients across multiple domains, including cognition, daily functioning, and behavior, and to provide realistic expectations for patients and caregivers throughout the course of the disease. This review provides a basic overview of approved AD therapies, discusses some pharmacologic and nonpharmacologic treatment stra...Continue Reading

Associated Proceedings Papers


Jul 16, 2013·International Journal of Law and Psychiatry·Jakov Gather, Jochen Vollmann
Dec 27, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Maria Laura BolognesiCarlo Melchiorre
Apr 8, 2011·Science Translational Medicine·David M HoltzmanAlison M Goate
Aug 22, 2012·BMC Medical Education·Angela L JeffersonDarby Morhardt
Feb 2, 2012·The Primary Care Companion to CNS Disorders·Roy YaariP N Tariot
Jun 13, 2012·The Primary Care Companion to CNS Disorders·Roy YaariP N Tariot
Sep 4, 2012·The Primary Care Companion to CNS Disorders·Roy YaariP N Tariot
Feb 20, 2013·Molecular Psychiatry·V K RamananAlzheimer’s Disease Neuroimaging Initiative
Oct 26, 2011·Journal of Drug Targeting·Mohammad FazilJaved Ali
Apr 29, 2015·Alzheimer's Research & Therapy·Martin FarlowAna Graf
Feb 7, 2009·Journal of Chromatography. a·Teris A van Beek, Paola Montoro
Mar 19, 2009·American Journal of Alzheimer's Disease and Other Dementias·Carl H SadowskyUS38 study group
Dec 30, 2017·BMC Complementary and Alternative Medicine·Yujie JiaKun Nie
May 9, 2015·Chemical Biology & Drug Design·Abdul HameedJamshed Iqbal
Dec 10, 2009·Clinical Drug Investigation·J Simon BellKaisu H Pitkälä
Jul 11, 2009·Expert Review of Neurotherapeutics·Werner J Geldenhuys, Cornelis J Van der Schyf
Jul 28, 2011·Medicinal Research Reviews·Rafael LeónJosé Marco-Contelles
Apr 21, 2018·The Journal of Pharmacology and Experimental Therapeutics·Soichi KawaharadaShuji Kaneko
Aug 30, 2019·Journal of Biomolecular Structure & Dynamics·Kader SahinSerdar Durdagi
Feb 26, 2015·Pharmacological Reports : PR·Anil Kumar Ekavali
Jun 14, 2018·Frontiers in Pharmacology·Bushra ShalSalman Khan
Mar 20, 2020·International Journal of Molecular Sciences·Stefano MuscatMarco Agostino Deriu
May 9, 2020·International Journal of Molecular Sciences·Md Tanvir KabirMohamed M Abdel-Daim
Jul 17, 2010·Neuroscience and Behavioral Physiology·E B ManukhinaI Yu Malyshev
Nov 5, 2008·CNS Spectrums·J L Cummings
Jan 25, 2017·Evidence-based Complementary and Alternative Medicine : ECAM·Dennis ChangAlan Bensoussan


Dec 1, 1994·Clinical Pharmacology and Therapeutics·K W LangeM B Youdim
Oct 15, 1998·Alzheimer Disease and Associated Disorders·Martha Clare MorrisD A Evans
Dec 5, 1998·British Journal of Clinical Pharmacology·P J TiseoL T Friedhoff
Feb 16, 1999·Brain Pathology·W R Markesbery, J M Carney
Apr 6, 1999·Archives of Neurology·R C PetersenE Kokmen
Apr 24, 1999·BMJ : British Medical Journal·T Bayer
Feb 19, 2000·The American Journal of Clinical Nutrition·F NourhashemiJ L Albarede
Apr 20, 2000·European Journal of Pharmacology·A Maelicke, E X Albuquerque
May 5, 2000·The Cochrane Database of Systematic Reviews·J Birks, L Flicker
May 5, 2000·The Cochrane Database of Systematic Reviews·J BirksM Tsolaki
Sep 2, 2000·Current Opinion in Neurology·P Scheltens, E S Korf
Nov 7, 2000·The American Journal of Medicine·D Praticò, N Delanty
Feb 24, 2001·Journal of Psychopharmacology·N R DunnS A Shakir
Oct 19, 2001·Journal of Neurology, Neurosurgery, and Psychiatry·K RockwoodD Wilkinson
Nov 28, 2001·Alzheimer Disease and Associated Disorders·L E HebertD A Evans
Dec 26, 2001·Archives of Neurology·R C PetersenB Winblad
Jan 5, 2002·Neurobiology of Aging·P P Zandi, J C Breitner
Jan 17, 2002·The New England Journal of Medicine·B A in t' VeldB H Stricker
Apr 16, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·G S J MannensW Meuldermans
Jun 28, 2002·Trends in Neurosciences·Carl W Cotman, Nicole C Berchtold
Aug 7, 2002·Clinical Pharmacokinetics·Michael W JannGary W Small
Aug 21, 2002·JAMA : the Journal of the American Medical Association·Heidi D NelsonJanet D Allan
Aug 28, 2002·American Journal of Epidemiology·Joan LindsayIan McDowell
Nov 8, 2002·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Wendy J LorentzSoo Borson
Jan 22, 2003·The Cochrane Database of Systematic Reviews·J Birks, L Flicker
Feb 13, 2003·Archives of Neurology·Martha Clare MorrisRobert S Wilson
Feb 13, 2003·Archives of Neurology·Jose A LuchsingerRichard Mayeux
Mar 15, 2003·International Psychogeriatrics·Martin Farlow
Apr 4, 2003·The New England Journal of Medicine·Barry ReisbergMemantine Study Group
Apr 5, 2003·Neurochemical Research·Ezio Giacobini

Related Concepts

Familial Alzheimer Disease (FAD)
Ginkgo biloba Whole
Antioxidant Effect
Anti-Inflammatory Agents, Non-Steroidal
Vitamin E Assay
Cholinesterase Inhibitors, Reversible
Alzheimer's Disease
Antiparkinson Agents
Cholinesterase Inhibitors

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Synapse Loss as Therapeutic Target in MS

As we age, the number of synapses present in the human brain starts to decline, but in neurodegenerative diseases this occurs at an accelerated rate. In MS, it has been shown that there is a reduction in synaptic density, which presents a potential target for treatment. Here is the latest research on synapse loss as a therapeutic target in MS.

Artificial Intelligence in Cardiac Imaging

Artificial intelligence (ai) techniques are increasingly applied to cardiovascular (cv) medicine in cardiac imaging analysis. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

Social Learning

Social learning involves learning new behaviors through observation, imitation and modeling. Follow this feed to stay up to date on the latest research.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Single Cell Chromatin Profiling

Techniques like ATAC-seq and CUT&Tag have the potential to allow single cell profiling of chromatin accessibility, histones, and TFs. This will provide novel insight into cellular heterogeneity and cell states. Discover the latest research on single cell chromatin profiling here.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells.

Related Papers

Pharmacological Research : the Official Journal of the Italian Pharmacological Society
Ezio Giacobini
Proceedings of the National Academy of Sciences of the United States of America
Nigel H GreigDebomoy K Lahiri
© 2020 Meta ULC. All rights reserved